Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
198 hedge funds and large institutions have $795M invested in Impax Laboratories, Inc. in 2016 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 72 increasing their positions, 63 reducing their positions, and 34 closing their positions.
15% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 34
14% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 63
1% more funds holding
Funds holding: 196 → 198 (+2)
46% less capital invested
Capital invested by funds: $1.46B → $795M (-$667M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
97% less call options, than puts
Call options by funds: $19K | Put options by funds: $657K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NTC
North Tide Capital
Boston,
Massachusetts
|
+$34.2M |
| 2 |
Two Sigma Investments
New York
|
+$17.6M |
| 3 |
Renaissance Technologies
New York
|
+$15.6M |
| 4 |
Two Sigma Advisers
New York
|
+$13.9M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$8.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$89.8M |
| 2 |
HP
Hound Partners
New York
|
-$30.2M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$25.1M |
| 4 |
KAM
Krensavage Asset Management
New York
|
-$24.5M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$17.4M |
IPXL Hedge Fund Activity: Q4 2016 in Review
198 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q4 2016, worth a combined $795M — down 46% from $1.46B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new IPXL positions and 34 closed out — a net gain of 5 holders — while 72 added to existing stakes and 63 trimmed.
The largest buyer was North Tide Capital, opening a new position worth an estimated $34.2M. The largest seller was OrbiMed, exiting entirely with an estimated $89.8M sold.
- 198 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q4 2016, up from 196 in Q3 2016.
- Funds reported $795M of Impax Laboratories, Inc. stock for Q4 2016, down 46% quarter-over-quarter.
- 39 funds opened new Impax Laboratories, Inc. positions in Q4 2016 and 34 closed out, a net change of +5 holders.
- The largest Impax Laboratories, Inc. buyer in Q4 2016 was North Tide Capital, an estimated $34.2M added.
- The largest Impax Laboratories, Inc. seller in Q4 2016 was OrbiMed, an estimated $89.8M sold.
Based on aggregated 13F filings for Q4 2016.